Improving HER2 testing reproducibility in HER2-low breast cancer
Authors:
Open Access
- 1 January 2022
- journal article
- research article
- Published by OAE Publishing Inc. in Cancer Drug Resistance
- Vol. 5 (4) , 882-888
Abstract
HER2 is a pillar biomarker in breast cancer, and it is assessed by immunohistochemistry (IHC) using a three-tier scoring system and reflex in situ hybridization (ISH) for IHC score 2+. Novel HER2-directed antibody-drug conjugates have demonstrated significant antitumor activity in breast cancers with low levels of HER2 expression, i.e. IHC score 1+ or ISH-negative IHC score 2+. Both primary and acquired resistance to anti-HER2 therapies remains a challenge in the treatment of breast cancers according to the HER2 positivity continuum. Thus, the ability to precisely discriminate among HER2-zero, HER2-low, and HER2-positive breast cancers is no longer a mere academic exercise. HER2 testing criteria, guidelines, and quality controls are re-gaining momentum for this new clinical need. Therefore, all preanalytical and analytical variables that might trouble the sensitivity and reproducibility of this test should be carefully considered to address all possible issues and open all possible therapeutic opportunities for breast cancer patients.Keywords
This publication has 32 references indexed in Scilit:
- Overcoming Therapeutic Resistance in HER2-Positive Breast Cancers with CDK4/6 InhibitorsCancer Cell, 2016
- Antibody-drug conjugates—an emerging class of cancer treatmentBritish Journal of Cancer, 2016
- Accuracy and Reproducibility of HER2 Status in Breast Cancer Using Immunohistochemistry: A Quality Control Study in Tuscany Evaluating the Impact of Updated 2013 ASCO/CAP RecommendationsPathology and Oncology Research, 2014
- Human Breast Cancer Cells Harboring a Gatekeeper T798M Mutation in HER2 Overexpress EGFR Ligands and Are Sensitive to Dual Inhibition of EGFR and HER2Clinical Cancer Research, 2013
- Current Challenges for HER2 Testing in Diagnostic Pathology: State of the Art and Controversial IssuesFrontiers in Oncology, 2013
- Frequent Mutational Activation of the PI3K-AKT Pathway in Trastuzumab-Resistant Breast CancerClinical Cancer Research, 2012
- Human epidermal growth factor receptor 2 (HER2) immunoreactivity: specificity of three pharmacodiagnostic antibodiesHistopathology, 2011
- Genetic heterogeneity in HER2 testing in breast cancer: panel summary and guidelines.Archives of Pathology & Laboratory Medicine, 2009
- EXEL-7647 Inhibits Mutant Forms of ErbB2 Associated with Lapatinib Resistance and Neoplastic TransformationClinical Cancer Research, 2008
- American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast CancerJournal of Clinical Oncology, 2007